Brief: Aeterna Zentaris - Preclinical Program To Qualify Macimorelin For Clinical Development As Potential Treatment Option For Amyotrophic Lateral Sclerosis
17/05/2021 13:21
May 17 (Reuters) - Aeterna Zentaris Inc AEZS.TO :
* AETERNA ZENTARIS - PRECLINICAL PROGRAM TO QUALIFY
MACIMORELIN
FOR CLINICAL DEVELOPMENT AS POTENTIAL TREATMENT OPTION FOR
AMYOTROPHIC LATERAL SCLEROSIS
Source text for Eikon: ID:nGNX3W527P
Further company coverage: AEZS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on COSCIENS Biopharma
See all newsBrief: COSCIENS Acquires Nualtis Corp
Refile: Canada's COSCIENS Biopharma Q2 net loss narrows on higher sales
Canada's COSCIENS Biopharma Q1 net income turns positive on discontinued German operations
Brief: Cosciens Biopharma Inc Not Aware Of Material Undisclosed Information Amid Recent Trading Activity
Brief: Cosciens Provides Strategic Update